Menu Search
Equities

Ikena Oncology Inc

IKNA:NMQ

Ikena Oncology Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.76
  • Today's Change0.07 / 4.14%
  • Shares traded139.27k
  • 1 Year change-57.38%
  • Beta0.5014
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Ikena Oncology Inc had revenues fall -41.35% from 15.62m to 9.16m, though the company grew net income from a loss of 68.77m to a smaller loss of 68.17m.
Gross margin--
Net profit margin-3,617.57%
Operating margin-4,092.19%
Return on assets-40.52%
Return on equity-44.54%
Return on investment-43.17%
More ▼

Cash flow in USDView more

In 2023, Ikena Oncology Inc increased its cash reserves by 99.33%, or 60.38m. Cash Flow from Financing totalled 75.98m or 829.48% of revenues. In addition the company used 79.74m for operations while cash from investing totalled 64.14m.
Cash flow per share-1.40
Price/Cash flow per share--
Book value per share2.96
Tangible book value per share2.96
More ▼

Balance sheet in USDView more

Ikena Oncology Inc has a strong Balance Sheet and has consistently grown its cash reserves over the last four years to total 119.89m.
Current ratio18.22
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.